Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 8/20 | 0.95 |
| ▸ | MMP2 | P08253 | 5/20 | 0.76 |
| ▸ | ADAM17 | P78536 | 15/20 | 0.76 |
| ▸ | MMP9 | P14780 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783379 | 0.98 | MMP13 (1.00) | MMP13MMP2ADAM17MMP9 | |
| Trifluoroacetic Acid SCHEMBL6785994 | 0.96 | MMP13 (0.88) | MMP13MMP2ADAM17MMP9 | |
| Trifluoroacetic Acid SCHEMBL7547767 | 0.93 | MMP13 (0.91) | MMP13MMP2ADAM17MMP9 | |
| Trifluoroacetic Acid SCHEMBL6787546 | 0.93 | MMP13 (0.91) | MMP13MMP2ADAM17MMP9 | |
| SCHEMBL6787256 | 0.89 | MMP13 (0.84) | MMP13MMP2ADAM17MMP9 | |
| SCHEMBL6790270 | 0.89 | MMP2 (0.96) | MMP13MMP2ADAM17MMP9 | |
| SCHEMBL6786764 | 0.87 | MMP2 (1.00) | MMP13MMP2ADAM17MMP9 | |
| SCHEMBL6794928 | 0.86 | ADAM17 (1.00) | MMP13MMP2ADAM17MMP9 | |
| SCHEMBL6795271 | 0.86 | ADAM17 (1.00) | MMP13MMP2ADAM17MMP9 | |
| Trifluoroacetic Acid SCHEMBL6788954 | 0.85 | MMP13 (0.78) | MMP13MMP2ADAM17MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825215-B2 | N-HYDROXY-2-(2-(((4-((2-METHYL-4-QUINOLINYL)METHOXY)PHENYL) -SULFONYL)METHYL)-2-PYRROLIDINYL)ACETAMIDE, FOR EXAMPLE AND OTHER QUINOLINE CONTAINING N-HYDROXYACETAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | claimed |
| US-20020137734-A1 | 1,1-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-26 | — | — | US | claimed |
| US-6825215-B2 | N-HYDROXY-2-(2-(((4-((2-METHYL-4-QUINOLINYL)METHOXY)PHENYL) -SULFONYL)METHYL)-2-PYRROLIDINYL)ACETAMIDE, FOR EXAMPLE AND OTHER QUINOLINE CONTAINING N-HYDROXYACETAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20020137734-A1 | 1,1-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137734-A1 | 1,1-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | MMP1, MMP8, MMP9 | MMP13 15/4885MMP2 6/4885ADAM17 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.